Over a 10-year period, METS-IR effectively predicted CV events among patients with PsA, with values greater than 2.48 at baseline conferring the greatest risk.

Among patients with PsA, MetS is associated with certain degenerative changes in the spine and entheses but not with peripheral or axial radiographic damage.

Objectives MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of ...